Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Left bundle branch pacing (LBBP) dramatically outperformed traditional right ventricular pacing (RVP) in the OptimPacing trial — so much so that the study was stopped early. Patients with AV block who received LBBP had far fewer deaths, heart failure hospitalizations, and cases of pacing-induced cardiomyopathy. Experts are now asking whether it's time to update clinical guidelines to make LBBP the default first-line strategy.
The OptimPacing trial, presented at the American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine, was halted early after left bundle branch pacing (LBBP) proved strikingly superior to conventional right ventricular pacing (RVP) in patients with atrioventricular (AV) block requiring permanent pacemakers. The international randomized trial enrolled 702 patients across China, Europe, and the U.S., with 685 included in the final analysis.
At a median follow-up of 35.1 months, LBBP significantly reduced the composite risk of all-cause mortality, heart failure hospitalization, and pacing-induced cardiomyopathy compared to RVP. Notably, zero patients in the LBBP group developed pacing-induced cardiomyopathy — versus nearly 12% in the RVP group. Experts at the AHA meeting are now questioning whether current Heart Rhythm Society guidelines, which give physiologic pacing only a Class IIa recommendation, need an upgrade.
By the Numbers:
Why it matters: For patients who need permanent pacemakers, where the lead is placed makes a critical difference. LBBP's ability to mimic the heart's natural electrical pathway could prevent cardiomyopathy and reduce hospitalizations — potentially reshaping pacing practice worldwide.
